Odyssey Therapeutics, Inc.
ODTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001882782
No open-market purchases or sales by Odyssey Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $652.9M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Superinvestors holding ODTX, Q2 2026
1 superinvestor reports holding Odyssey Therapeutics, Inc. on Form 13F, worth $15.6M in total. Weight is Odyssey Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| HHLR Advisors (Hillhouse)Zhang Lei | 1.9% | 831,656 | $15.6M | New |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ODTX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end